UNSPSC 51172144: Pargeverine or pargeverine hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C21H23NO3 and C21H23NO3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers UC61HM8FX0 and XT63P694CJ, the base compound being chemically known as benzeneacetic acid, alpha-phenyl-alpha-(2-propynyloxy)-, 2-(dimethylamino)ethyl ester but generally known as pargeverine, which bears US NIH Compound Identifier 17700.

UNSPSC 51172144 Pargeverine or pargeverine hydrochloride is a Commodity code that maps to drug-testing and pharmaceutical-supply procurement at the state and local level. Recent opportunities show state and local governments using this code to solicit specimens for drug-testing programs, generic pharmaceuticals for bulk distribution to public facilities, and direct-to-manufacturer prescription fulfillment capabilities. The issuing bodies span county corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of participating jurisdictions. The scope extends from specimen collection and laboratory testing services (immunoassay and mass spectrometry confirmation, oral fluid and hair testing alternatives) to generic multi-source pharmaceutical sourcing and pharmacy benefit program modernization.

Activity is concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with optional renewal, requiring SAMHSA or CAP lab certification and per-test pricing across five-panel and six-panel drug screens plus ancillary testing at two collection sites in Plano and McKinney. The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026, requiring cGMP and DSCSA compliance and relationships with authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs for a future formal solicitation. Contract vehicles range from single-vendor awards to multi-vendor arrangements with pricing penalties and administrative fees.